This study demonstrates a reduction in breakthrough medication requirements, particularly benzodiazepines, for patients sedated with dexmedetomidine at end of life (EOL).

The dexmedetomidine cohort required less breakthrough interventions per day compared with the standard care group, the reduction was significant.

There was a significant difference in benzodiazepine requirements, with the dexmedetomidine cohort requiring fewer doses per day than the standard care cohort.

Anticholinergics were more commonly utilized in the standard care cohort but there was no significant difference.

Opioid requirements were similar across cohorts with comparable rates of breakthrough use and infusion increases.

Read More